Develop and commercialize therapies for rare diseases. Market Chenodal for the treatment of radiolucent gallstones. Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
Average growth of 39% a year over the last 4 years. Red columns mark years that ended in a loss.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
This company is not turning a profit, so the market is pricing its sales instead: 12.9× for every dollar of annual revenue.
Against companies in its own sector, it looks cheaper than 30% of them.
Analysts' average target sits 3% below today's price.
Executive selling isn’t always bad news; people sell for personal reasons too. Still, the thin buying side is worth noting.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
Over the last 4 years, sales grew about 39% a year on average.
Sales run at $490.7M a year. A small number, but proof the product has real buyers.
A loss of $25.5M against $490.7M in annual sales.
The balance sheet offers little cushion against a rough stretch. Report-card grade: 15/100.
Today’s price already includes part of tomorrow’s optimism. Report-card grade: 30/100.
On our five-subject report card, TVTX sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: TVTX is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.